Clinical trial · Observational
Assessing Depression in a Geriatric Cancer Population
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this study is to learn more about how we measure depression in elderly cancer patients (patients aged 70 and older). Depression is one of the most common causes of emotional distress in the elderly and continues to be under-recognized. This is a problem because depression can have a negative impact on quality of life. The symptoms of depression are linked to poor health outcomes and higher costs of health care. In fact, depression is one of the top five concerns facing the elderly today.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- 1
- description
- 150 patients will be women with breast cancer (75 early stage and 75 late stage)
- label
- 2
- description
- 150 will be men with prostate cancer (75 early stage and 75 late stage)
Primary outcomes (1)
- measure
- Test the sensitivity and specificity of the Geriatric Depression Scale-Short Form and two other widely used assessments of depression to detect major and minor depression in a geriatric breast and prostate cancer population.
- timeFrame
- 2 years
Secondary outcomes (1)
- measure
- To develop a cut-off score for the GDS that is specific to a cancer population.
- timeFrame
- 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age 70 and older 2. Diagnosis of early or late stage prostate cancer, or diagnosis of early or late stage breast cancer 3. Actively engaged in one of the following cancer treatments: chemotherapy, radiation therapy, hormone therapy 4. Able to provide informed consent 5. Ability to converse, write and read English Exclusion Criteria: 1.Major psychopathology or cognitive impairment likely in the judgment of the research staff to interfere with the participation or completion of the protocol.
References
Publications (0)
Data not yet available